Depth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint’s Ross
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC’s ‘Closing Bell’ to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more. Source link